NCT03416686Active, not recruiting
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer. It could constitute a minimally invasive and feasible therapeutic alternative in ambulatory, allowing a reduction of the tumoral volume sufficient to limit the symptoms even to induce a tumor remission, a normalization of the tumoral markers and a better quality of life. The aim of this study is to evaluate the anti-tumor echographic efficacy at 12 months of radiofrequency on lymph node (LN) metastasis of thyroid cancer
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 7 Dec 2017
- Start date
- 16 Apr 2019
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Thyroid cancer
- NCT number
- NCT03416686
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 16 Apr 2019 to the primary completion date, 30 Jun 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who can't follow the instructions of RF therapy or who can't be followed during 2 years in order to meet the objectives of the study
- Beta hormone chorionic gonadotrope (HCG) positive test (pregnancy) before RF therapy
Other illness
- Hypersensitivity to local anesthetic
- Poor general condition (performance status Eastern Cooperative Oncology Group (ECOG) \> 1)
Lab values
- Congenital or acquired hemostasis abnormality, anticoagulant therapy or double platelet antiaggregatory (aspirin and clopidogrel)
Other
- Location of LN metastasis with significant risk of local complication (nervous, vascular) according baseline ultrasound assessment
- Patient carrier of a pacemaker or a defibrillator
- Survival estimated less than 12 months
- Non affiliation to a social security
- Pregnant or breast feeding women at the time of RF
- Baseline cervical ultrasound, by expert operator trained to RF, not fulfilling feasibility criteria for RF realisation because of the location of LN metastasis or the way to reach it
- Controlateral recurrent palsy on nasofibroscopy
Who the study is looking for
- Patients over age of 18 years
- with differentiated thyroid cancer (papillary, follicular) histologically confirmed, and absence of anaplastic component
- Previous treatment by total thyroidectomy and cervical lymph node dissection.
- Previous treatment by at least 1 therapeutic radioactive iodine (minimum activity 740MBq)
- Persistence on cervical ultrasound of at least 1 cervical metastatic lymph node, visible at ultrasound, small diameter between ≥10 mm and ≤30mm, volume maximum 20ml, spotted on a picture, and confirmed by cyto-punction
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Américain de Paris Coordinator of this site? Confirm its status | Neuilly-sur-Seine | France | Unknown status |
| Hôpital Laiboisière Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Hopital Saint Louis Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.